Collective launches Zero Interest Option Exercise Loan Read More

Areteia Therapeutics stock

Areteia Therapeutics Stock

HealthTech
Looking to sell Areteia Therapeutics Stock or Options? Get a free valuation
Founded: 2022Funding to Date: $425M
Visit website

Areteia Therapeutics developed an oral medication designed to assist patients suffering from eosinophilic asthma. The innovative drug from this company works by inhibiting the maturation of eosinophils before they can cause damage to the airways. This could potentially provide a manageable treatment option for millions of patients grappling with this severe type of asthma. With Areteia Therapeutics' first potential oral drug for eosinophilic asthma, patients can regain better control of their disease and their lives.

Investors Include:

Viking Global Investors, Maverick Capital, Saturn Partners, Bain Capital Life Sciences, Population Health Partners, GV, Marshall Wace, ARCH Venture Partners, Sanofi, Access Biotechnology.

Own Areteia Therapeutics stock or options?

Get an instant valuation

  • Completely free
  • 100% confidential & secure
  • Takes less than a minute
100% private & secure